Effects of Apalutamide on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer
Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This phase I trial tests the molecular effects of apalutamide in patients with non-muscle
invasive bladder cancer. Apalutamide is in a class of medications called androgen receptor
inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to
stop the growth and spread of tumor cells. Previous studies have suggested that expression of
a protein called epidermal growth factor receptor (EGFR) on tumor cells is related to bladder
cancer disease progression. This trial may help doctors evaluate if apalutamide has any
effect on EGFR expression in patients with non-muscle invasive bladder cancer.